Abstract: Objective To explore the clinical efficacy of using diammonium glycyrrhizinate capsules for the treatment of elderly patients with liver dysfunction. Methods A total of 80 elderly patients with liver dysfunction from March 2020 to March 2023 who were admitted in Binzhou Bincheng District People's Hospital were selected, and randomly divided into the study group and the control group, each group consisted of 40 cases. The control group was treated with glucuronic acid tablets, and the study group was treated with diammonium glycyrrhizinate capsules.The clinical efficacy,liver function, oxidative stress indicators,and adverse reactions in both groups were compared. Results The total effective rate of treatment in the study group was higher than that in the control group, and the difference was statistically significant(P<0.05). After treatment,the alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), and gamma glutamyl transpeptidase (γ-GT) levels in both groups were decreased(P<0.05), and in comparison of the control group, the study group was lower,and the study group was lower than the control group, with a statistically significant difference(P<0.05). After treatment,the superoxide dismutase (SOD) and glutathione (GSH) levels in both groups were increased, the malondialdehyde (MDA) levels were decreased The levels of SOD and GSH in the study group were higher than those in the control group, and the level of MDA was lower, with statistical significance (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The application of diammonium glycyrrhetinic acid capsules in the treatment of elderly liver dysfunction can improve clinical efficacy,improve patient liver function, alleviate oxidative stress reactions,and not lead to an increase in adverse reactions.

Key words: diammonium glycyrrhetinic acid capsules, elderly liver dysfunction, clinical efficacy, safety